# cBioPortal Usage Analysis Report

*Generated on 2025-12-19 11:35:23*

---

## Summary Statistics

- **Total Papers Analyzed**: 13890
- **Year Range**: 2012 - 2026
- **Classified from Full PDF**: 697 (5.0%)
- **Classified from Abstract Only**: 13120 (94.5%)
- **Most Common Analysis Type**: Gene expression analysis
- **Most Common Cancer Type**: Other solid tumor
- **Most Common Data Source**: TCGA

## Data Collection & Limitations

This analysis is based on papers that cite the three main cBioPortal publications:

- PMID 37668528
- PMID 23550210
- PMID 22588877

**Total citations in database**: 14,834 papers
**Unique papers** (deduplicated): 13,890 papers
**Papers citing multiple cBioPortal publications**: 944 papers

**Important limitation**: The PubMed eutils API returns fewer citations than shown on the PubMed website. 
For example, PMID 37668528 shows 750 citations on PubMed's website but the API only returns 407 citations. 
This is a known limitation of the eutils citation indexing system. 
Our analysis is based on the subset of citations available through the API.

## Citation Overlap Analysis

- Papers citing only 1 cBioPortal publication: 12,946
- Papers citing 2 cBioPortal publications: 944
- Papers citing all 3 cBioPortal publications: 0

## Visualizations

### Usage Analysis Overview

![Usage Analysis](../plots/usage_analysis.png)

*Four-panel visualization showing analysis types, cancer types, data sources, and temporal trends.*

### Research Areas

![Research Areas](../plots/research_areas.png)

*Distribution of research areas utilizing cBioPortal.*

---

## Top Analysis Types

1. Gene expression analysis: 10628 papers
2. Survival analysis: 7324 papers
3. Mutation analysis: 6150 papers
4. Pathway analysis: 5554 papers
5. Copy number analysis: 3192 papers
6. Multi-omics integration: 2582 papers
7. Other: 1614 papers
8. Drug response/resistance: 26 papers
9. Methods/Tools development: 23 papers
10. Tumor evolution: 17 papers

## Top Cancer Types

1. Other solid tumor: 4858 papers
2. Pan-cancer: 2916 papers
3. Breast cancer: 2374 papers
4. Lung cancer: 1505 papers
5. Colorectal cancer: 1079 papers
6. Prostate cancer: 947 papers
7. Glioma/Brain cancer: 945 papers
8. Melanoma: 643 papers
9. Leukemia/Lymphoma: 589 papers
10. Not specified: 505 papers

## Data Sources Used

1. TCGA: 8248 papers
2. Multiple sources: 4878 papers
3. Custom/Private data: 3784 papers
4. Not specified: 2105 papers
5. METABRIC: 429 papers
6. MSK-IMPACT: 168 papers
7. ICGC: 111 papers
8. GENIE: 87 papers
9. GEO: 3 papers
10. GDSC: 2 papers

## How cBioPortal is Being Used

1. Citation only: 8389 papers
2. Web-based analysis: 4393 papers
3. Web-based visualization: 2130 papers
4. Data download/export: 2099 papers
5. Query interface: 73 papers
6. API access: 21 papers
7. Expression analysis: 14 papers
8. Unclear: 12 papers
9. Database/Resource: 2 papers
10. Not applicable - cBioPortal not used: 2 papers
11. Survival analysis: 1 papers
12. Group comparison: 1 papers

## cBioPortal Features Used

1. Not specified: 9211 papers
2. Expression analysis: 2771 papers
3. Query interface: 2637 papers
4. Survival analysis: 1583 papers
5. Download data: 1431 papers
6. Mutation Mapper: 255 papers
7. Group comparison: 188 papers
8. OncoPrint: 79 papers
9. Copy number analysis: 37 papers
10. Enrichment analysis: 36 papers

## Where Analysis Was Performed

1. Unclear: 8768 papers
2. cBioPortal platform: 1524 papers
3. External (downloaded data): 1251 papers
4. Mixed: 722 papers
5. ["Unclear"]: 697 papers
6. ["cBioPortal platform"]: 320 papers
7. ["External (downloaded data)"]: 289 papers
8. ["Mixed"]: 243 papers
9. Not applicable - This study does not use cBioPortal: 1 papers
10. ="External (downloaded data)": 1 papers
11. Not applicable - cBioPortal not used: 1 papers

## Most Frequently Queried Genes

1. TP53: 779 papers
2. KRAS: 384 papers
3. EGFR: 316 papers
4. PIK3CA: 272 papers
5. BRAF: 247 papers
6. PTEN: 242 papers
7. MYC: 195 papers
8. CDKN2A: 177 papers
9. BRCA1: 148 papers
10. ERBB2: 147 papers
11. BRCA2: 141 papers
12. IDH1: 113 papers
13. RB1: 100 papers
14. CD274: 100 papers
15. NRAS: 93 papers
16. ARID1A: 91 papers
17. CTNNB1: 82 papers
18. APC: 81 papers
19. ESR1: 81 papers
20. ATM: 81 papers

---

# Bibliometric Analysis

*Analysis of metadata from citing papers*

## Geographic Distribution

1. USA: 4261 papers
2. China: 4034 papers
3. United Kingdom: 1209 papers
4. Germany: 726 papers
5. Canada: 560 papers
6. Italy: 497 papers
7. Japan: 478 papers
8. Spain: 376 papers
9. Australia: 353 papers
10. France: 343 papers
11. South Korea: 325 papers
12. India: 285 papers
13. Netherlands: 233 papers
14. Sweden: 214 papers
15. Switzerland: 161 papers
16. Brazil: 149 papers
17. Austria: 122 papers
18. Belgium: 114 papers
19. Israel: 113 papers
20. Singapore: 101 papers

## Top Journals Citing cBioPortal

1. Cancers: 617 papers
2. Scientific reports: 567 papers
3. Oncotarget: 445 papers
4. Frontiers in oncology: 438 papers
5. International journal of molecular sciences: 382 papers
6. Nature communications: 375 papers
7. PloS one: 240 papers
8. Oncogene: 215 papers
9. Frontiers in genetics: 213 papers
10. BMC cancer: 196 papers
11. Aging: 168 papers
12. Frontiers in immunology: 167 papers
13. Cancer research: 155 papers
14. Clinical cancer research : an official journal of the American Association for Cancer Research: 155 papers
15. Oncology letters: 134 papers

## Publication Types

1. Journal Article: 12113 papers
2. Research Support, Non-U.S. Gov't: 4543 papers
3. Research Support, N.I.H., Extramural: 2475 papers
4. Review: 1174 papers
5. Research Support, U.S. Gov't, Non-P.H.S.: 532 papers
6. Case Reports: 113 papers
7. Research Support, N.I.H., Intramural: 100 papers
8. Preprint: 65 papers
9. Meta-Analysis: 65 papers
10. Comparative Study: 58 papers

## Funding Agencies

1. NCI NIH HHS: 10349 papers
2. NIGMS NIH HHS: 1457 papers
3. Cancer Research UK: 692 papers
4. NIH HHS: 594 papers
5. National Natural Science Foundation of China: 441 papers
6. NIDDK NIH HHS: 412 papers
7. NCATS NIH HHS: 402 papers
8. NHLBI NIH HHS: 378 papers
9. Medical Research Council: 353 papers
10. NINDS NIH HHS: 321 papers
11. Wellcome Trust: 254 papers
12. NIAID NIH HHS: 252 papers
13. NIDCR NIH HHS: 219 papers
14. NIEHS NIH HHS: 208 papers
15. NHGRI NIH HHS: 192 papers

## Research Topics (MeSH Terms)

1. Humans: 7864 papers
2. Female: 2966 papers
3. Animals: 2317 papers
4. Gene Expression Regulation, Neoplastic: 2257 papers
5. Cell Line, Tumor: 2253 papers
6. Male: 1900 papers
7. Prognosis: 1852 papers
8. Mutation: 1790 papers
9. Mice: 1662 papers
10. Biomarkers, Tumor: 1503 papers
11. Neoplasms: 1291 papers
12. Signal Transduction: 1229 papers
13. Middle Aged: 1152 papers
14. Cell Proliferation: 1101 papers
15. Breast Neoplasms: 947 papers
16. Aged: 920 papers
17. Gene Expression Profiling: 782 papers
18. Adult: 736 papers
19. Lung Neoplasms: 722 papers
20. Tumor Microenvironment: 641 papers

## Recent Papers Using cBioPortal

### The Roles of TOPK in Tumorigenesis and Development: Structure, Mechanisms, Pathways, and Therapeutic Implications. (2026.0)

- **Research Area**: ['Review/Commentary', 'Biomarker discovery']
- **Cancer Type**: ['Pan-cancer']
- **Usage**: This is a comprehensive review paper on TOPK (T-LAK cell-originated protein kinase) in cancer. While the paper discusses TOPK expression patterns, mutations, and clinical significance across various cancer types, the abstract and introduction provided do not explicitly describe how cBioPortal was used. The paper appears to synthesize data from multiple sources including TCGA to discuss TOPK's role in tumorigenesis, but specific cBioPortal usage details are not evident in the provided sections.

### EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']
- **Cancer Type**: ['Breast cancer']
- **Usage**: Based on the abstract and introduction provided, cBioPortal usage is not explicitly mentioned in these sections. The study uses Caris Life Sciences data for NGS and survival analysis, but no direct reference to cBioPortal is found in the provided text. The paper may cite cBioPortal in the full text or methods section not provided here, but from the available content, cBioPortal usage cannot be confirmed.

### Secreted frizzled-related protein 1a regulates hematopoietic development in a dose-dependent manner. (2026.0)

- **Research Area**: ['Review/Commentary']
- **Cancer Type**: ['Leukemia/Lymphoma']
- **Usage**: This paper focuses on developmental biology research using zebrafish models to study hematopoietic stem and progenitor cell (HSPC) development. The paper mentions observations in hematopoietic cancers where SFRP1 variants can promote or inhibit tumor development, but there is no explicit description of cBioPortal usage in the abstract or introduction provided. The citation appears to be contextual, relating their developmental findings to cancer biology observations.

### Cohesin mutations and chromatin changes in cancer. (2026.0)

- **Research Area**: ['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']
- **Cancer Type**: ['Pan-cancer']
- **Usage**: This is a review paper focusing on cohesin mutations across different cancer types. While the paper discusses recurrent mutations in cohesin complex genes (SMC1A, SMC3, RAD21, STAG1, STAG2) identified through cancer exome sequencing studies, the abstract and introduction do not explicitly describe direct usage of cBioPortal. The paper likely cites cBioPortal as a reference resource for cancer genomics data, but specific usage details are not provided in the available text.

### Loss of FAT1 drives cyclophosphamide resistance in breast cancer via the Wnt/Î²-Catenin pathway. (2026.0)

- **Research Area**: ['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']
- **Cancer Type**: ['Breast cancer']
- **Usage**: The paper mentions conducting comprehensive genomic and transcriptomic analysis to identify FAT1 as a tumor suppressor gene in breast cancer. While cBioPortal is cited, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used in the study. The research primarily focuses on patient-derived organoids (PDOs) and whole exome sequencing (WES) analysis of custom patient samples.

### A Glycerophospholipid Metabolism-Based Prognostic Model Guides Osteosarcoma Therapy. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine', 'Pathway analysis']
- **Cancer Type**: ['Other solid tumor']
- **Usage**: The paper does not explicitly describe how cBioPortal was used in the methodology. While the study analyzes mutation profiling and copy number alterations in osteosarcoma, there is no clear mention of cBioPortal in the abstract or introduction provided. The citation of cBioPortal may be for reference purposes or the actual usage details may be in the methods section not provided.

### Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Precision medicine']
- **Cancer Type**: ['Other solid tumor']
- **Usage**: The study used MSK-IMPACT targeted genomic sequencing panel data for 18 patients with metastatic clear-cell renal cell carcinoma. Genomic data including fraction of genome altered and CDKN2A copy number loss were correlated with disease-free survival outcomes. The analysis appears to have been performed using institutional data, likely accessed through cBioPortal infrastructure for MSK-IMPACT data.

### Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Precision medicine']
- **Cancer Type**: ['Other solid tumor']
- **Usage**: The study used cBioPortal to access and analyze the TCGA-BLCA cohort (n=412) as a validation cohort for muscle-invasive bladder cancer. The authors likely used cBioPortal to obtain METTL3 expression data and clinical information from TCGA-BLCA to validate their findings regarding the association between METTL3 expression loss and poor survival outcomes in MIBC patients.

### Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR. (2026.0)

- **Research Area**: ['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']
- **Cancer Type**: ['Lung cancer']
- **Usage**: Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental characterization of a novel NOTCH2-NTRK1 fusion gene using in vitro and in vivo models, phosphoproteomic analyses, and protein interaction studies. cBioPortal may be cited in the references but its specific use is not described in the provided text.

### Integrative analysis identifies PIGK as an oncogenic glycosylphosphatidylinositol transamidase subunit with prognostic, immunological, and therapeutic relevance in head and neck cancer. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']
- **Cancer Type**: ['Other solid tumor']
- **Usage**: The paper used cBioPortal to analyze PIGK expression, genomic alterations (copy number gains), and correlations with mutations in other genes (FAT1, CDKN2A, NOTCH1, CASP8) in head and neck cancer. The platform was likely used to access TCGA head and neck cancer data for multi-omics integration including gene expression, copy number analysis, and mutation profiling. The study integrated cBioPortal data with additional validation using tissue microarrays and in vitro experiments.
